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1 
ABSTRACT 
 
Background: The primary role of a trial’s Data Monitoring Committee (DMC) is to 
ensure the safety of enrolled patients. In stroke trials, safety is monitored typically by 
comparing death and stroke specific events between treatment groups. DMCs may 
also have the remit for monitoring efficacy depending on the aims of the trial. We 
hypothesised that functional outcome at end of follow-up, a measure of efficacy, is 
also a powerful measure of safety and tested this in a systematic review. 
 
Methods: Acute stroke trials with a negative outcome or which were stopped 
prematurely on the grounds of safety were sought systematically from searches of 
electronic databases and published reviews. Information on early and late death, 
impairment, and functional outcome, and the presence of a DMC, were recorded for 
each trial. The results for each outcome measure were ranked within each trial to 
determine which was most statistically efficient in detecting hazard. 
 
Results: 14 trials were included. The most efficient outcomes for detecting hazard 
were: late death or disability, 6 trials; early death, 4 trials (2 of which tested 
thrombolysis); late death, 3 trials; late death or impairment, 1 trial. Early death was 
insensitive to hazard in all 6 trials where late death or dependency was most 
sensitive. Two trials (both phase II) did not report the presence of a DMC. 
 
Conclusions: Functional outcome at end of follow-up can be sensitive to hazard and 
should be included in all assessments of safety in stroke trials, whether or not efficacy 
itself is being assessed. 
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What is the take-home message for clinicians? 
All stroke trials should have a Data Monitoring Committee. Functional outcome has 
been shown to be sensitive to hazard. Data monitoring committees should assess 
functional outcome alongside safety outcomes in stroke trials.   
 
How did you gather the info you considered in your review? 
Non-confounded randomised controlled trials involving patients with acute stroke were 
identified June 2005 and repeated in March 2006. Trials had to be negative or have 
stopped prematurely on the grounds of potential or definite hazard. 
 
Key words: stroke; clinical trial; data monitoring committees; functional outcome; 
efficacy; impairment 
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INTRODUCTION 
 
The principle role of Data Monitoring Committees (DMC) in clinical trials is to 
safeguard the interests of study participants.[1] In practice, this means ensuring that 
patients are not exposed to unnecessary risks. Typically, DMCs will review the trial’s 
protocol prior to recruitment (and any subsequent protocol amendments), ensure the 
study’s scientific integrity, and review the primary trial report prior to publication to 
ensure accuracy.[1, 2] During the study, the DMC will assess unblinded data in the 
context of ‘safety’; if patients randomised to active therapy fare significantly worse 
than those in the control group then the DMC will usually recommend to the Trial 
Steering Committee that the study should be modified or stopped. In many cases, 
‘efficacy’ (typically functional outcome in a stroke trial) will also be assessed; 
differences in outcome in favour of the active treatment group may also lead the DMC 
to recommend that the trial should stop (or change in design). Finally, in some cases 
(usually involving commercially-sponsored trials), the DMC will also perform pre-
specified futility analyses; these aim to stop the trial early if there is no reasonable 
chance that it will find a positive treatment effect. The structure, composition and 
modus operandi of DMCs have been defined recently.[2] 
 
Which events to assess when monitoring safety can vary considerably but those 
relevant to stroke include death, impairment and deterioration. Intervention-specific 
safety events will also be monitored, e.g. symptomatic intracranial bleeding in trials of 
antithrombotic or fibrinolytic agents. Whether DMCs should also review functional 
outcome (e.g. Barthel Index, modified Rankin Scale) when assessing safety, 
irrespective of whether efficacy itself is being considered, remains controversial. 
Safety and efficacy variables overlap considerably and generally run in parallel, i.e. a 
treatment which increases death may also worsen functional outcome. Nevertheless, 
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reviewing functional outcome may come at a price if not performed appropriately, e.g. 
performing formal statistical comparisons will amount to an interim analyses and 
reduce study power. 
 
We hypothesised that functional outcome measured at the end of follow-up would be 
sensitive to hazard just as death or impairment are. We performed a systematic 
review to test this hypothesis by using data from published trials of potential or 
overtly hazardous interventions in acute stroke. 
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METHODS 
 
Trial identification 
Non-confounded randomised controlled trials involving patients with acute stroke were 
sought through searches of The Cochrane Library (including systematic reviews, e.g. 
of neuroprotectants and thrombolysis [3, 4]), PUBMED, the stroke trials register at 
http://www.strokecenter.org/, and reviews of treatment for acute stroke;[5] searches 
were performed in June 2005 and repeated in March 2006. (Figure 1)Trials had to be 
negative (as opposed to positive or neutral) or have stopped prematurely on the 
grounds of potential or definite hazard; we excluded neutral or positive studies since 
they would not have tested the hypothesis that functional outcome at end of follow-up 
is a potential measure of hazard. Identified trials were excluded if data were missing 
for death, or combined death or disability/dependency. Neutral trials reporting a 
negative outcome in one or more subgroups were also excluded. 
 
Analyses 
Data on conventional measures of safety (death, deterioration, impairment, e.g. 
based on National Institutes of Health Stroke Scale or Scandinavian Stroke Scale) and 
efficacy (combined death or disability, e.g. Barthel Index, modified Rankin Scale, 
Glasgow Outcome Scale) at or shortly after end-of-treatment, and at end-of-follow-
up, were obtained from trial publications. Death, impairment and functional outcome 
were considered to imply hazard if their rate was significantly higher (p<0.05) in the 
group of patients randomised to active treatment. Data from phase II trials with two 
or more active treatment groups were merged to increase event rates (as is usually 
done in systematic reviews); hence, the control group was compared with the 
aggregated data from the active groups. [6-8] In phase III trials with multiple active 
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treatment groups, data from the highest dose group were compared with control since 
hazard/toxicity is usually associated with higher rather than lower doses.[9-11] 
 
The results of statistical analyses were taken from trial publications where available, 
or calculated using Fisher’s exact test for 2x2 data 
(http://www.graphpad.com/quickcalcs/index.cfm). The results of significance tests for 
each outcome were ranked within each trial to determine which outcome was most 
efficient statistically in detecting hazard. Significance was set at p<0.05 and two-sided 
tests were performed. 
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RESULTS 
 
Included trials 
Fourteen trials fulfilled the inclusion criteria; event rates for safety and efficacy 
variables are given in table 1.  
 
Neuroprotection 
Aptiganel (CNS-1102, NMDA receptor modulator) was assessed in a phase II/III trial 
(AASI) of 900 patients with ischaemic stroke.[3] The study was suspended with 628 
patients recruited on the advice of the DMC with a trend to a difference in mortality; 
hazard was apparent in patients receiving high dose aptiganel (table 1).[9] The 
ASSIST programme assessed selfotel (competitive NMDA receptor antagonist) in 
patients with acute ischaemic stroke.[12] Two concurrent phase III trials were 
suspended early on the advice of the DMC because of an imbalance in mortality; 
overall, 567 patients (of an intended 1,840) had been enrolled when the TSC 
terminated of the trial.[12] Gavestinel (GV150526, glycine antagonist) was tested in a 
phase IIb trial;[8] the protocol was changed with DMC involvement when transient 
asymptomatic reversible elevations in bilirubin were noted. However, hazard was 
apparent in the form of worse functional outcome although this seems to have been 
largely explained by an imbalance in stroke severity at baseline. A phase II trial of 
sipatrigine (BW 919C89, sodium channel blocker, trial 137-104) ran to completion;[3] 
hazard was present in the form of a worse functional outcome at final follow-up in the 
patients receiving active treatment. 
 
A phase IIb dose comparison trial of lubeluzole was terminated prematurely (232 
patients recruited of 270) on the advice of the DMC due to an imbalance in mortality 
between the higher dose of lubeluzole versus placebo.[11] The EAST phase III trial of 
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enlimomab (anti-ICAM monoclonal antibody) in 625 patients with acute ischaemic 
stroke ran to completion; patients randomised to active treatment had increased 
impairment and disability.[13] A phase IIa dose-escalation trial (n=95) of a 
haemoglobin-based oxygen carrier, DCLHb, found that it increased the odds of a poor 
functional outcome.[6] INWEST was a phase IIb/III trial (n=295) comparing two 
doses of intravenous nimodipine with placebo;[10] functional outcome was worse in 
patients randomised to nimodipine and the DMC recommended early closure. Two 
trials of tirilazad mesylate, a free radical scavenger, are included.[14] STIPAS was a 
phase IIa dose-escalation trial which ran to completion; however, functional outcome 
was worse in patients receiving tirilazad.[7] The TESS II phase III trial of tirilazad was 
stopped early following recommendation by the DMC that hazard was present; by the 
time the trial actually stopped a few weeks later it was neutral although with a strong 
negative trend.[14] Overall, a meta-analysis of tirilazad mesylate was negative on two 
measures (Barthel Index, Glasgow Outcome Scale) of functional outcome.[14] 
 
Thrombolysis 
The ATLANTIS A phase III trial of alteplase enrolled patients between 0 and 6 hours 
after ischaemic stroke; the DMC recommended stopping the trial because of safety 
concerns (increased severe impairment, symptomatic intracranial haemorrhage, and 
death) in patients treated in the 5-6 hour group.[15] (The trial was subsequently re-
started as ATLANTIS B with recruitment limited to 3-5 hours post stroke onset.[16]) 
Intravenous streptokinase was tested in three phase III trials. In two of the trials, the 
DMC alerted the TSCs that potential hazard was present in the form of an increase in 
early mortality. Recruitment was stopped early, after 310 patients of a planned 600 in 
MAST-E, and after 340 of 600 in ASK.[17, 18] The result in the third trial, MAST-I, 
was complicated by its factorial design involving both streptokinase and aspirin; the 
combination of streptokinase and aspirin was associated with an increase in early 
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death.[19] The DMC recommended that the TSC should review the trial’s data in the 
light of ASK and MAST-E; the TSC decided, with some dissent in interpretation of the 
results,[20] that the trial should stop with 622 patients recruited out of a planned 
1,500.  
 
Excluded trials 
Four trials potentially exhibiting hazard were excluded: (i) a study of ZK200775 
(AMPA antagonist) did not report data on functional outcome;[21] (ii) a trial of 
intravenous nimodipine has only been reported in abstract form;[22] and (iii) a phase 
II/III trial of trafermin (basic fibroblast growth factor) [5] has not been published at 
all. A further trial of trafermin was neutral overall and therefore excluded although it 
had a negative sub-group.[23] 
 
Death, impairment and disability/dependency 
When ranking the efficiency of outcomes identifying hazard by trial, functional 
outcome (combined death or disability) at end of follow-up was the most sensitive 
measure of potential hazard in 6 trials (table 2). The number of trials for the other 
outcomes were: early death, 4; death at end of follow up, 3; and death or impairment 
at end of follow up, 1. 
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DISCUSSION 
 
Whether DMCs should include functional outcome data in their reviews of safety 
(irrespective of whether efficacy itself is being considered) has been a long-standing 
question. We hypothesised that measures of efficacy such as the Barthel Index and 
modified Rankin Scale would provide important information on safety. The results of 
this systematic review support this hypothesis with six of the 14 included trials finding 
that functional outcome was the most ‘efficient’ measure of safety (assessed as the 
smallest ‘p-value’).[3, 6-9, 13]  Indeed, a DMC reviewing conventional safety data 
based on death alone in these six studies would not have identified significant hazard. 
(Interestingly, functional outcome was also most sensitive to potential hazard in a 
negative sub-group of the excluded neutral trial, namely those patients treated with 
trafermin 10 mg within 5 hours of stroke onset.[23]) 
 
In 7 of the remaining trials,[11, 12, 14, 15, 17-19] death (early or end of trial) was 
the more powerful safety measure. Three reasons may explain the discrepancy 
between these trials and the six above, First, certain interventions such as 
thrombolytics (as tested in ASK, ATLANTIS A, MAST-E and MAST-I [15, 17-19]) may 
increase death (through promoting early intracranial haemorrhage) whilst reducing 
disability.[4] Hence, treatment will move the outcomes of death, and disability, in 
opposite directions so that the combination of death or dependency may not differ 
appreciably. Second, some studies analysed functional outcome using dichotomous 
statistical approaches (with ordinal data collapsed into binary data). We and others 
have shown that ordinal tests (e.g. ordinal regression, Mann-Whitney U, robust ranks, 
bootstrapping of the mean) are usually more powerful than dichotomous tests (e.g. 
Chi-square) when analysing functional data based on the modified Rankin Scale or 
Barthel Index.[24] Last, reliable functional outcome data relating to end of follow-up 
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often lags behind the reporting of end of treatment events such as death so the 
amount of efficacy data available for assessment by the DMC may be insufficient, 
especially early on in the life of a trial. 
 
The implication of not assessing efficacy variables such as Barthel Index and modified 
Rankin Scale when considering safety is that a signal of hazard may be missed. Not 
only would this situation be detrimental to patients, investigators and sponsors, but 
the DMC members may lay themselves open to legal action on the grounds of 
inadequate assessment of the data. 
 
It might be thought that safety measures should only focus on events occurring 
during treatment, or soon after, rather than later on. The adverse effects of short-
term treatment are likely to occur early whilst many events occurring later have little 
directly to do with the index stroke or its treatment, e.g. falls or myocardial infarction. 
Nevertheless, early events are few in number relative to those accumulating by 3 
months; for example, in control patients early death occurred in up to 18.2% of cases 
whilst the frequency of combined death or dependency ranged between 7.7% and 
81.8% (median 43.5%, table 1). Statistically, maximum power from an analysis 
based on binary data occurs when the event rate approximates 50% so assessments 
based on low numbers of events (e.g. death) will be underpowered relative to 
functional outcome. In reality, it is likely that there will be a balance between the 
limited power of assessing early mortality, and the delay in collecting end of trial 
events such as death or disability, at least early on in the trial. 
Our study aimed to systematically review the use of efficacy measures as markers of 
safety in acute stroke trials which were either overtly negative or where they were 
stopped prematurely on safety grounds. However, identification of such stroke trials 
using standard literature search criteria was complex, largely because many trialists 
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describe neutral trials as negative; hence, we may have missed some relevant 
studies. It is difficult to estimate exactly how many acute stroke trials have been 
completed in total but those involving putative neuroprotectants or thrombolytics 
number in excess of 200. From a statistical perspective, we might expect to find 10 
negative trials (assuming significance is achieved at 5%) just on the grounds of 
chance. However, many of the trials we included are likely to reflect true negative 
studies, in part because hazard was seen across a spectrum of outcomes, and 
because their statistical significance was considerably smaller than 5% (table 2). An 
exception to this is the Lub-Int 4 study [11] which was probably falsely negative since 
the meta-analysis of all lubeluzole trials is neutral.[25] Further complicating the 
study, the included trials did not all report measures of death and impairment, used 
different scales for measuring disability, and dichotomised functional outcome scales 
in different places. Importantly, we used two-sided statistical tests since these allow 
assessment of benefit as well as hazard. Additionally, we kept the focus of this study 
on the use of efficacy measures as potential markers of hazard, and have not 
assessed other potential safety measures, e.g. those based on blood or 
neuroradiological biomarkers. 
 
Why should DMCs not consider efficacy variables in the context of safety? One 
explanation may come from the title of committees (or boards) which varies markedly 
between trials [26] (and even within their publications); commonly used names 
include data monitoring committee (DMC),[2, 5, 17] data and safety monitoring board 
(DSMB),[1, 12] data and safety monitoring committee (DSMC),[27] independent data 
monitoring committee (IDMC),[27] independent data and safety monitoring 
committee (IDSMC),[9, 28] independent safety monitoring committee (ISMC),[29] 
international safety committee (ISC),[13] and safety monitoring committee 
(SMC).[10, 29, 30] The emphasis on ‘safety’ in some titles may explain, in part, 
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apparent neglect of efficacy measures. It is clear that a short, single and non-
restrictive term should be used in future trials, e.g. Data Monitoring Committee.[2, 
26] 
 
It is pertinent to ask if there are drawbacks to allowing the DMC to view efficacy data 
when considering safety. First, the decision-making process for deciding whether a 
trial will continue, change or stop will increase in complexity as more data are 
assessed; in theory, this might increase the risk of the DMC making a mistake. 
Nevertheless, access to efficacy data is likely to improve the ability of the DMC to 
identify potential hazard so the issue of data complexity is probably of secondary 
importance. Furthermore, pre-specifying stopping rules for efficacy will reduce the risk 
that a trial is ended inappropriately early on the grounds of potential hazard. Second, 
sponsors and trial steering committees (TSC) may be concerned about ‘leakage’ of 
efficacy data from the DMC to the outside world. Sharing outcome data of any sort 
from an ongoing trial could introduce several problems, not least damaging centre and 
patient recruitment, and having effects on a company’s share price. It is vital that 
DMCs fulfil their responsibility not to share confidential data outside the committee. 
Last, regulatory authorities may consider that unblinded ‘looks’ at efficacy data 
constitute interim analyses. This view is inappropriate since DMC reviews of data do 
not normally, or even have to, involve formal statistical comparisons, unless as part of 
a planned interim or futility analysis, or if hazard is suspected. In these respects, it is 
vital that the DMC carries the confidence of the academic or commercial sponsor, TSC, 
investigators, and regulatory authorities (as relevant).[28] 
 
Three points from this work can be concluded. First, all multicentre phase II and III 
trials should have a DMC.[26] Second, it is vital that all completed trials are published 
so we can all learn from their experience. This is particularly relevant where studies 
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apparently identified hazard, as with nimodipine and trafermin.[5, 22] Last, we 
believe that DMCs should always review functional outcome data when assessing 
safety to avoid missing signals of potential hazard. Such efficacy data should include 
that collected at the end of trial follow-up. TSC and sponsors should support the DMC 
by providing all necessary efficacy and safety data. The view that DMCs should review 
both safety and efficacy data is supported by others.[26, 28] 
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FIGURE LEGENDS 
Figure 1 
Flow chart of search strategy 
 
